German biotech company BioNTech has announced a project aimed at creating a highly efficacious vaccine to help eradicate malaria, while expanding vaccine production capacity across Africa. BioNTech will develop a first-generation mRNA vaccine using a known antigen, the CSP protein, the clinical trial for which is expected to start at the end of 2022.
from Engineering News | Home https://ift.tt/3iPMhdH
